Comprehensive Multidimensional Liquid Chromatography-Mass Spectrometry for the Characterization of Charge Variants of a Bispecific Antibody.

automation bispecific antibodies cation-exchange chromatography critical quality attributes mass spectrometry multiattribute monitoring multidimensional liquid chromatography online HPLC product variants

Journal

Journal of the American Society for Mass Spectrometry
ISSN: 1879-1123
Titre abrégé: J Am Soc Mass Spectrom
Pays: United States
ID NLM: 9010412

Informations de publication

Date de publication:
07 Dec 2022
Historique:
pubmed: 29 11 2022
medline: 15 12 2022
entrez: 28 11 2022
Statut: ppublish

Résumé

Identification and further characterization of antibody charge variants is a crucial step during biopharmaceutical drug development, particularly with regard to the increasing complexity of novel antibody formats. As a standard analytical approach, manual offline fractionation of charge variants by cation-exchange chromatography followed by comprehensive analytical testing is applied. These conventional workflows are time-consuming and labor-intensive and overall reach their limits in terms of chromatographic separation of enhanced structural heterogeneities raised from new antibody formats. For these reasons, we aimed to develop an alternative online characterization strategy for charge variant characterization of a therapeutic bispecific antibody by online mD-LC-MS at middle-up (2D-LC-MS) and bottom-up (4D-LC-MS) level. Using the implemented online mD-LC-MS approach, all medium- and even low-abundant product variants previously identified by offline fraction experiments and liquid chromatography mass spectrometry could be monitored. The herein reported automated online mD-LC-MS methodology therefore represents a complementary and in part alternative approach for analytical method validation including multiattribute monitoring (MAM) strategies by mass spectrometry, offering various benefits including increased throughput and reduced sample handling and combined protein information at intact protein and peptide level.

Identifiants

pubmed: 36442848
doi: 10.1021/jasms.2c00296
pmc: PMC9732868
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2319-2327

Références

J Chromatogr A. 2014 Mar 28;1335:81-103
pubmed: 24365115
J Immunol Methods. 2001 Feb 1;248(1-2):7-15
pubmed: 11223065
ACS Omega. 2022 Jan 19;7(4):3671-3679
pubmed: 35128275
J Am Soc Mass Spectrom. 2008 Nov;19(11):1643-54
pubmed: 18707900
Biochim Biophys Acta Gen Subj. 2017 Dec;1861(12):3096-3108
pubmed: 28887103
J Pharm Biomed Anal. 2020 May 10;183:113178
pubmed: 32086124
Anal Chem. 2022 Jun 14;94(23):8136-8145
pubmed: 35545869
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92
pubmed: 21690412
Anal Chem. 2019 Jan 2;91(1):240-263
pubmed: 30380827
J Pharm Biomed Anal. 2017 Oct 25;145:482-503
pubmed: 28746908
J Am Soc Mass Spectrom. 2021 Aug 4;32(8):2062-2071
pubmed: 33687195
J Pharm Biomed Anal. 2020 Jul 15;186:113251
pubmed: 32251978
Anal Chem. 2013 Jan 15;85(2):715-36
pubmed: 23134362
Commun Biol. 2018 Apr 5;1:28
pubmed: 30271914
Trends Pharmacol Sci. 2016 Dec;37(12):993-1008
pubmed: 27836202
Anal Chem. 2018 Feb 6;90(3):2119-2125
pubmed: 29264912
MAbs. 2016;8(2):331-9
pubmed: 26655595
Protein Eng. 1996 Jul;9(7):617-21
pubmed: 8844834
Cell Mol Immunol. 2020 May;17(5):451-461
pubmed: 32313210
Talanta. 2021 Nov 1;234:122628
pubmed: 34364437
J Chromatogr A. 2020 Mar 29;1615:460740
pubmed: 31796250
PLoS One. 2012;7(1):e30295
pubmed: 22272329
Anal Chim Acta. 2021 Nov 1;1184:339015
pubmed: 34625261
MAbs. 2015;7(4):732-42
pubmed: 25996192
MAbs. 2012 Sep-Oct;4(5):578-85
pubmed: 22820257
Data Brief. 2020 Mar 16;30:105435
pubmed: 32274410
Analyst. 2021 Feb 7;146(3):747-769
pubmed: 33410843

Auteurs

Ingrid Grunert (I)

Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.

Katrin Heinrich (K)

Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.

Michael Hingar (M)

Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.

Juliane Ernst (J)

Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.

Martin Winter (M)

Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.

Katrin Bomans (K)

Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.

Katharina Wagner (K)

Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.

Arnaud Fevre (A)

Pharma Technical Development, Hoffmann-La Roche, 4070 Basel, Switzerland.

Dietmar Reusch (D)

Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.

Manfred Wuhrer (M)

Center for Proteomics and Metabolomics, Leiden University Medical Center, 2333 Leiden, The Netherlands.

Patrick Bulau (P)

Pharma Technical Development, Hoffmann-La Roche, 4070 Basel, Switzerland.

Articles similaires

Humans Self-Control Longitudinal Studies Child, Preschool Child
Humans Pisum sativum Breast Neoplasms Tandem Mass Spectrometry Plant Extracts

Why experimental variation in neuroimaging should be embraced.

Gregory Kiar, Jeanette A Mumford, Ting Xu et al.
1.00
Humans Neuroimaging Brain Reproducibility of Results Magnetic Resonance Imaging

Classifications MeSH